Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices

Active Research Project
Sarah M. Cheal, Ph.D.
Last Updated: 
June 16, 2022

We are currently developing a novel bivalent radiohapten class that we refer to as “gemini” for “twin haptens” to achieve improved therapeutic indices (TIs) via cooperative binding at intratumoral bispecific anti-tumor/anti-DOTA antibody (BsAb).

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065